Oral administration of a bacterial immunomodulator enhances murine intestinal lamina propria and Peyer's patch lymphocyte traffic to the lung: possible implications for infectious disease prophylaxis and therapy.
LW50020, a bacterial immunomodulator, is a preparation consisting of seven bacteria, commonly causing respiratory disease. When given orally, LW50020 has been shown to enhance the host defense of the respiratory tract. Intestinal lamina propria lymphocytes (LPL), Peyer's patch lymphocytes (PPL), and splenocytes from BALB/c mice gavaged either with LW50020 or carrier alone were isolated, labeled with either H33342, a supravital nuclear fluorochrome, or 51Cr, and injected i.v. into untreated, age-matched BALB/c mice. Two hours later, spleen, liver, lung, kidneys, Peyer's patch, and mesenteric lymph nodes of the recipients were harvested and screened for the presence of labeled cells. LPL from mice gavaged with carrier only (controls) migrated preferentially to the lung, PPL equally well to the lung, and the spleen and splenocytes were found mostly in the spleen. LPL and PPL from LW50020-treated mice were found in significantly larger numbers in the lungs of recipients than LPL and PPL from control animals. Both labeling techniques gave roughly the same results. Sixty-five per cent of LPL in the lung were Thy-1.2+ and 20% B cells. These findings should contribute to the understanding of parameters necessary for the assessment of the mode of action and efficacy of immunomodulation and vaccination via the mucosa-associated lymphoid tissue.
Ruedl
C
C
Institute for General and Experimental Pathology, University of Innsbruck, Medical School, Austria.
Albini
B
B
Böck
G
G
Wick
G
G
Wolf
H
H
Albin
B
B
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology*; D000284:Administration, Oral; D000818:Animals; D015703:Antigens, CD / Q000032:analysis; D000954:Antigens, Surface / Q000096:biosynthesis; D001428:Bacterial Vaccines / Q000494:pharmacology*; D002465:Cell Movement / Q000187:drug effects; D003140:Communicable Disease Control; D003141:Communicable Diseases / Q000628:therapy; D004847:Epithelial Cells; D004848:Epithelium / Q000276:immunology; D005260:Female; D007413:Intestinal Mucosa / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D007421:Intestine, Small / Q000166:cytology / Q000276:immunology; D017493:Leukocyte Common Antigens; D008168:Lung / Q000166:cytology / Q000276:immunology*; D008214:Lymphocytes / Q000502:physiology*; D008562:Membrane Glycoproteins / Q000096:biosynthesis; D051379:Mice; D008807:Mice, Inbred BALB C; D010581:Peyer's Patches / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D013154:Spleen / Q000166:cytology / Q000276:immunology; D018800:Thy-1 Antigens
D000276:Adjuvants, Immunologic; D015703:Antigens, CD; D000954:Antigens, Surface; D001428:Bacterial Vaccines; C078795:LW 50020; D008562:Membrane Glycoproteins; D018800:Thy-1 Antigens; D017493:Leukocyte Common Antigens